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Late-stage differentiation of 
embryonic pancreatic β-cells 
requires Jarid2
Sara Cervantes1,2, Marta Fontcuberta-PiSunyer1,3, Joan-Marc Servitja1,2, Rebeca Fernandez-
Ruiz1,2, Ainhoa García1,2, Lidia Sanchez1,2, Young-Sook Lee4, Ramon Gomis1,2,5,6 &  
Rosa Gasa1,2
Jarid2 is a component of the Polycomb Repressor complex 2 (PRC2), which is responsible for genome-
wide H3K27me3 deposition, in embryonic stem cells. However, Jarid2 has also been shown to exert 
pleiotropic PRC2-independent actions during embryogenesis. Here, we have investigated the role of 
Jarid2 during pancreas development. Conditional ablation of Jarid2 in pancreatic progenitors results in 
reduced endocrine cell area at birth due to impaired endocrine cell differentiation and reduced prenatal 
proliferation. Inactivation of Jarid2 in endocrine progenitors demonstrates that Jarid2 functions after 
endocrine specification. Furthermore, genome-wide expression analysis reveals that Jarid2 is required 
for the complete activation of the insulin-producing β-cell differentiation program. Jarid2-deficient 
pancreases exhibit impaired deposition of RNAPII-Ser5P, the initiating form of RNAPII, but no changes 
in H3K27me3, at the promoters of affected endocrine genes. Thus, our study identifies Jarid2 as a fine-
tuner of gene expression during late stages of pancreatic endocrine cell development. These findings 
are relevant for generation of transplantable stem cell-derived β-cells.
Diabetes mellitus (DM) is a complex disease that results from failure of β-cells to secrete enough insulin to main-
tain normoglycemia. Seminal studies have demonstrated that it is possible to generate insulin-secreting β–cells 
from ESCs and iPSCs through the stepwise addition of growth factors and chemical compounds1–3, recapitulating 
the different stages of in vivo endocrine cell differentiation. Even though the in vitro generated β-cells are able to 
prevent or ameliorate hyperglycemia in mouse models of diabetes, their gene expression profile and functionality 
still differs from that of mature human β-cells2, 3.
The endocrine compartment of the pancreas is constituted by α- (glucagon), β- (insulin), δ- (somatostatin), 
PP- (pancreatic polypeptide) and ε-(ghrelin) cells, which reside in the islets of Langerhans, surrounded by exo-
crine tissue (acinar and ductal). Between embryonic day (e)13.5 and e15.5, the bulk of endocrine cell formation 
unfolds in the trunk region of the pancreatic epithelium, a process known as the secondary transition. Transient 
expression of the master pro-endocrine transcription factor Neurogenin3 (Ngn3) in discrete cells within this 
domain generates monohormonal endocrine precursors, which will activate genes necessary for their endocrine 
function as they become mature endocrine cell types.
Although there is a broad knowledge of the transcriptional and signaling pathways that govern pancreatic 
cell-fate transitions, little is known about how chromatin modifiers regulate this process4–6. Only in the last 
few years we have begun to identify the chromatin modifications that accompany gene expression changes. 
The Polycomb Repressive Complex 2 (PRC2) catalyzes the trimethylation of lysine 27 in the tail of Histone H3 
(H3K27me3) through its enzymatic activities Ezh1 and Ezh2, resulting in transcriptional silencing. During 
mouse pancreas organogenesis, H3K27me3 is dynamically modified at the promoters of pancreatic and 
endocrine-specific genes7, 8. Ezh2 represses Pdx1 expression from the prospective liver domain, thus allowing 
liver specification while restricting the ventral pancreas9. Later during endocrine differentiation, Ezh2 represses 
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endocrine cell fate thus restraining endocrine cell mass formation. Accordingly, in mouse pancreatic explants 
and pancreatic cells obtained from hESCs, chemical inhibition of Ezh2 resulted in increased endocrine cell 
differentiation8.
Jarid2 (jumonji, AT rich interactive domain 2) is the founding member of the Jumonji-containing family of 
demethylases, even though it contains aminoacid substitutions that abolish its catalytic activity, and is a faculta-
tive component of PRC2. In ESCs, Jarid2 fine-tunes H3K27me3 levels and is essential for successful ESC differen-
tiation, most likely by priming PRC2 target genes for expression upon induction of differentiation10, 11. Recently, 
Jarid2 has been found in complexes with G9a/GLP and SETDB1 that regulate H3K9me3 levels (another repres-
sive mark)12–14 and thus, it may help coordinate methylation of H3K27 and H3K9. Deletion of Jarid2 in mice 
results in severe abnormalities in multiple organs including brain, heart, liver, spleen and blood tissues. Jarid2 also 
plays important roles in skin and muscle differentiation15–18. Additionally, two studies aimed at identifying genes 
enriched during pancreatic endocrine differentiation in vivo in mouse embryos, reported increased expression 
of Jarid2 in endocrine progenitors and descendants19, 20. Here we set out to determine the potential role of Jarid2 
in pancreatic and endocrine cell differentiation. We show that Jarid2 is required in progenitor cells to activate the 
β-cell gene expression program and thus generate fully differentiated β-cells.
Results
Ablation of Jarid2 in pancreatic progenitors results in reduced β-cell mass. Quantitative RT-PCR 
using whole pancreas lysates showed that Jarid2 is expressed throughout pancreatic development. While Jarid2 
mRNA levels are maintained relatively constant, Ezh1 expression is markedly increased and Ezh2 mRNA dimin-
ished at late gestation. In adult islets, Jarid2 mRNA is expressed at intermediate levels between Ezh1 and Ezh2 
(Fig. 1a).
To investigate the role of Jarid2 in pancreatic development, we generated mice in which Jarid2 was ablated 
from pancreatic progenitors (Pdx1-Cre;Jarid2flox/flox, from here on Jarid2Δpanc). In the absence of a reliable Jarid2 
antibody for immunostaining, we introduced the reporter R26-YFP allele to evaluate the extent of Cre-mediated 
recombination. Immunostaining against YFP revealed that at e15.5, most epithelial cells had recombined, except 
for some cells located in the trunk and tip areas, thus proving epithelium-specific but mosaic Pdx1-driven Cre 
recombination (Fig. 1b). To specifically determine the extent of Jarid2 downregulation, we quantified expression 
of the loxP-flanked Jarid2 exon3 and detected a 62% and 77% reduction compared to controls at e15.5 and e17.5, 
respectively (Fig. 1c). The remaining Jarid2 expression is possibly due to non-recombined epithelial cells and 
non-epithelial cell types, such as mesenchymal cells, which are present in reduced proportion as the pancreas 
develops21. The fact that the Jarid2 exon3 excision increased in older embryos (e17.5 vs e15.5) supports this 
notion.
At birth, the pancreas of Jarid2Δpanc mice appeared normal in morphology and size, as shown by quantification 
of pancreatic area (Fig. 1d). Yet, Jarid2Δpanc presented a 40% reduction in insulin positive fractional area and a 
marginal reduction in glucagon positive area (Fig. 1e). Accordingly, pancreatic insulin content was reduced by 
50% (Fig. 1f). To examine the endocrine compartment in more detail, we analyzed a series of endocrine and β-cell 
markers in Jarid2WT and Jarid2Δpanc tissues. At P0, endocrine cell clusters formed, although they appeared less 
compact and disaggregated in mutants than controls. These clusters in Jarid2Δpanc tissues appropriately expressed 
key transcription factors such as Pdx1, Nkx6-1, Nkx2-2, and the pan-endocrine marker and secretory granule 
protein ChromograninA or ChgA (Fig. 1g). The reduction in β-cell fractional area did not alter serum glucose 
levels in newborn animals (not shown). Adult Jarid2Δpanc mice also displayed normal fasting blood glucose, but 
were glucose intolerant at 9–11wks, while showing unaltered body weight (Supplementary Fig. S1). β-cell mass 
and islet size distribution were comparable to that of controls (Supplementary Fig. S1), indicating that postnatal 
β-cell expansion is able to compensate the reduction in β-cell number observed at birth. Yet, despite reaching 
normal β-cell mass, adult Jarid2Δpanc mice are glucose intolerant, which suggests that generated β-cells are not 
fully functional. Whether this is consequence of aberrant β-cell formation due to Jarid2 loss during pancreatic 
development or it results from the compensatory postnatal growth remains to be determined.
Endocrine cell formation is perturbed during the secondary transition in Jarid2Δpanc mice. As 
the bulk of β-cell neogenesis occurs during the secondary transition, we studied e15.5 pancreata from Jarid2Δpanc 
embryos and control littermates. Pancreatic morphology and size appeared normal, which was confirmed by 
quantification of pancreatic area on tissue sections (Fig. 2a). Likewise, endocrine (Pdx1, Nkx6-1, Nkx2-2), exo-
crine (Amy), ductal (Muc-1), and bipotent endocrine/ductal cell markers (Nkx6-1, Nkx2-2) were present and 
normally distributed (Fig. 2b). To uncover potential defects in the endocrine compartment, we quantified the 
mRNA encoding the three main pancreatic hormones, insulin (Ins1 and Ins2 genes), glucagon and somatostatin, 
in whole pancreatic lysates. Insulin and somatostatin expression were reduced by 50% while glucagon was reduced 
by only 18% (Fig. 2c). We next performed morphometric quantification of the endocrine positive area to deter-
mine whether the observed changes in expression correlated with reduced cell numbers. We found a 40% reduc-
tion in insulin positive area in Jarid2Δpanc embryos, while that of glucagon was not significantly affected (Fig. 2d). 
Immunofluorescence staining against Sox9+ bipotent ductal/endocrine demonstrated the normal distribution 
of this cell population (Fig. 2e). Likewise, distribution and number of Ngn3+ endocrine progenitors was not 
affected by Jarid2 loss (Fig. 2e). Altogether, these results reveal that Jarid2 is dispensable for endocrine specifica-
tion but it is required for differentiation of β- and δ-cells during the secondary transition.
Jarid2 is necessary for the transcriptional activation of pancreas-specific genes. To gain insights 
into the mechanisms underlying these differentiation defects, we performed a microarray analysis using RNA 
from whole Jarid2Δpanc and control e15.5 pancreases. Among the 217 genes that were significantly downregulated, 
Gene Ontology clustering revealed that the three top GO categories corresponded to a signature of pancreatic 
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functions (peptidase activity, regulation of secretion and hormone metabolic process) (Fig. 3a). We next interro-
gated how exocrine-enriched and endocrine-precursor-enriched genes were affected in the absence of Jarid2. A 
gene set of exocrine-enriched genes was generated from a previous study comparing the gene expression profiles 
of a panel of mouse tissues that included the pancreatic exocrine compartment as detailed in Methods22. On 
the other hand, genes enriched in Ngn3-positive endocrine progenitors were identified from a gene expression 
profiling dataset obtained from YFP-positive cells in the e15.5 embryonic pancreases of mice harboring a YFP 
Figure 1. Ablation of Jarid2 in pancreatic progenitors results in reduced β-cell mass at birth. (a) Quantification 
by qRT-PCR of Ezh1, Ezh2 and Jarid2 mRNAs at the indicated embryonic stages and in islets. For the embryonic 
pancreases, the kinetics of expression throughout development is represented relative to the expression at 
e12.5, while the expression in islets is shown relative to Tbp. Each data point represents mean ± SEM from 2–7 
independent mRNA extractions. The e12.5 and e13.5 data points are pools of several pancreases.  
(b) Immunofluorescence analysis of YFP expression (green) using an anti-GFP antibody that cross-reacts 
with YFP to assess recombination in Jarid2Δpanc mice at e15.5. Staining against Pdx1 (red) is used to mark the 
pancreatic epithelium. Nuclei were stained with Hoechst 33258 (blue). Scale bar: 50 μm. (c) Quantification by 
qRT-PCR of the relative expression of Jarid2 mRNA at the indicated embryonic stages in Jarid2WT (n = 11 and 
n = 6 at e15.5 and 17.5, respectively) and Jarid2Δpanc (n = 15 and n = 5 at e15.5 and 17.5, respectively) embryonic 
pancreases. Primers that amplify Jarid2 exon3 were used to detect its excision. Bars represent mean ± SEM; 
***p < 0.0001. (d) Morphometric analysis of Jarid2WT (n = 4) and Jarid2Δpanc (n = 4) pancreatic area in 
newborn mice (P0). Bars represent mean ± SEM. (e) Morphometric analysis of Jarid2WT (n = 4) and Jarid2Δpanc 
(n = 4) insulin and glucagon positive area in newborn mice (P0). Bars represent mean ± SEM; *p < 0.05. 
(f) Total insulin content from Jarid2WT (n = 5) and Jarid2Δpanc (n = 3) pancreases from newborn mice (P0) 
was quantified by ELISA. Bars represent mean ± SEM; *p < 0.01. (g) Immunofluorescence stainings against 
hormones, endocrine cell markers, and endocrine transcription factors in Jarid2WT and Jarid2Δpanc pancreases 
from newborn mice (P0) using anti-insulin, anti-glucagon, anti-somatostatin, anti-chromograninA (ChgA), 
anti-Pdx1, anti-Nkx6-1 and anti-Nkx2-2 antibodies. Nuclei were stained with Hoechst 33258 (blue). Endocrine 
clusters appeared disaggregated in Jarid2Δpanc but express the appropriate markers and factors. Scale bar: 50 μm.
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transgene inserted at the 3′UTR of Ngn3 (Ngn3eYFP/+ knock-add-on mice)19, 23. Remarkably, the top-most down-
regulated genes in Jarid2Δpanc pancreases were enriched in genes selectively expressed in endocrine and exocrine 
cells (red and green dots in the top-left quadrant of Fig. 3b, respectively), thus revealing a prominent role for 
Jarid2 in the regulation of pancreas-specific genes. Among the exocrine-enriched genes downregulated, we found 
several genes encoding pancreatic enzymes, including elastases (Cela2a, Cela3b, Cela1), Cbp1, Serine proteases 
(Prss1, Prss2, Prss3) and Amy1. Among the endocrine-enriched genes downregulated, we found MafA, Ins1, Ins2, 
Iapp, G6pc2, Npy, Scg2 and Slc30a8. These results underscore a role for Jarid2 in the activation of both the exo-
crine and endocrine gene expression programs. However, the fact that pancreas size and morphology appeared 
normal at birth (Fig. 1d), the unaltered body weight of adult Jarid2Δpanc mice (Fig. S1), and the apparently unal-
tered amylase expression pattern at e15.5 (Fig. 2b), indicated that the expression changes detected in exocrine 
genes did not result in physiological defects in this compartment.
In contrast, the altered phenotype of the embryonic endocrine compartment resulted in reduced β-cell 
mass and alterations in glucose homeostasis, defects that prompted us to perform a more detailed inspection of 
endocrine-precursor-enriched and islet-enriched genes. A gene set of islet-enriched genes was generated compar-
ing the gene expression profiles of a panel of mouse tissues including mouse pancreatic islets22. We found that the 
majority of genes enriched in endocrine progenitors (Ngn3-YFP-enriched) and islets (red and yellow dots, respec-
tively) remained unchanged (Fig. 3c). However, the genes with the highest enrichment scores in both endocrine 
progenitors (Ngn3-YFP) and islets (i.e. MafA, Ins1, Iapp, G6pc2 and Slc30a8) were downregulated in Jarid2Δpanc 
samples, indicating that loss of Jarid2 disrupts the expression of a subset of endocrine genes. Remarkably, the 
Figure 2. Ablation of Jarid2 in pancreatic progenitors results in reduced endocrine cell formation during 
the secondary transition. (a) Morphometric analysis of Jarid2WT (n = 3) and Jarid2Δpanc (n = 3) pancreatic 
area at e15.5. Bars represent mean ± SEM. (b) Immunofluorescence stainings against the indicated general 
(Pdx1, Foxa2), exocrine (Amy), ductal (Muc-1) and endocrine (Nkx6-1, Nkx2-2) cell markers in Jarid2WT 
and Jarid2Δpanc e15.5 pancreases confirms that the corresponding pancreatic compartments are appropriately 
formed at this stage. Nuclei were stained with Hoechst 33258 (blue). Scale bar: 100 μm. (c) Quantification by 
qRT-PCR of the relative expression of the three main pancreatic hormones Ins1+2, Gcg and Sst in Jarid2WT 
(n = 11) and Jarid2Δpanc (n = 15) e15.5 pancreases. Bars represent mean ± SEM; *p < 0.05, ***p < 0.0001. (d) 
Morphometric analysis of Jarid2WT (n = 3) and Jarid2Δpanc (n = 3) insulin and glucagon positive area in e15.5 
embryos. Columns represent mean ± SEM *p < 0.05. Representative image of the immunofluorescence staining 
against the three main pancreatic hormones, insulin (green), glucagon (red) and somatostatin (white) is shown 
on the right. Nuclei were stained with Hoechst 33258 (blue). Scale bar: 100 μm. (e) Immunofluorescence 
stainings against Sox9 (green) and Ngn3 (red) in Jarid2WT and Jarid2Δpanc shows that these markers are 
appropriately expressed at this stage. Nuclei were stained with Hoechst 33258 (blue). Scale bar: 100 μm. On the 
right, morphometric analysis of the number of Ngn3+ cells per epithelial (Pdx1+) area. Columns represent 
mean ± SEM (n = 4–5) and values are expressed relative to controls, which are given the number of 1.
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Figure 3. Jarid2 is necessary for the transcriptional activation of pancreas-specific genes. (a) Top GO categories 
identified by Gene Ontology analysis of the genes downregulated in the absence of Jarid2 in e15.5 mouse 
embryonic pancreases. (b) Volcano plot of all the genes represented in the microarray relating changes of gene 
expression and the corresponding statistical significances in Jarid2WT vs Jarid2Δpanc pancreases (X axis). Genes 
enriched in the Ngn3-YFP+ and exocrine cell populations are marked in red and green, respectively. Note 
that most of the genes in these two categories fall towards the left side of the plot, indicating that differentially 
expressed pancreas-specific genes are mainly downregulated in the absence of Jarid2. The identity of some of the 
most downregulated exocrine genes is indicated on the magnified graph. (c) Scatter plot of all genes represented 
in the microarray correlating their changes in gene expression in Jarid2WT vs Jarid2Δpanc pancreases (X axis) with 
their enrichment in Ngn3-YFP+ cells (left) and pancreatic islets40 (Y axis). Genes enriched in the Ngn3-YFP+ 
and islet cell populations are marked in red and orange on the left and right panels, respectively. Note that many 
of the genes most downregulated in Jarid2Δpanc vs Jarid2WT pancreases are enriched in Ngn3-YFP+ and/or islet 
cells. The identity of some of these genes is indicated on graphs.
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expression of genes known to be required for initial endocrine specification and/or differentiation such as Ngn3, 
Pax4, Rfx6, Arx, Myt1, Nkx2-2 and Isl1, remained unchanged in the absence of Jarid2 (Table S1).
We validated these observations by qRT-PCR in a larger set of samples and confirmed that, only a small 
fraction of the early endocrine specification genes appeared modestly reduced by loss of Jarid2 (i.e. Pax6, Insm1 
and NeuroD1) (Fig. 4a). In contrast, expression of several key β-cell differentiation/maturation genes (MafB, 
MafA, Pcsk1, Iapp and G6pc2), in addition to the hormones (Fig. 2c), was reduced (Fig. 4a). Intriguingly, expres-
sion of ChgA and ChgB, early markers of committed embryonic endocrine cells which are still detectable in 
de-differentiated insulin-negative β-cells24, was not altered in Jarid2Δpanc (Fig. 4a). These latter results were val-
idated by morphometric analysis of ChgA+ cells (Supplementary Fig. S2). Further, the relative proportion of 
double positive ChgA+/hormone+ was not significantly different between mutants and controls (Supplementary 
Fig. S2). Hence, loss of Jarid2 does not appear to impact commitment of the endocrine cell population.
Notably, analysis of gene expression in e17.5 embryos revealed that the defects in the expression of the three 
main pancreatic hormones as well as β-cell differentiation/maturation genes persist at later stages (Fig. 4b). The 
fact that most of the endocrine genes downregulated in Jarid2Δpanc embryos participate in β-cell maturation and/
or function rather than initial endocrine cell specification and commitment, suggests that islet endocrine cells 
form but do not fully differentiate in the absence of Jarid2.
Jarid2 is required downstream of Ngn3. Our results indicate that Jarid2 function is required most likely 
after Ngn3, since expression of early endocrine specification genes including Neurog3 remained unaltered. As 
an initial step, we assessed whether Jarid2 abundance was associated with endocrine differentiation. We isolated 
endocrine progenitors and their descendants from Ngn3-Cre;tdTomato e15.5 embryonic pancreases by FACS 
sorting and quantified expression of Jarid2 and of several PRC2 components. Interestingly, we found that while 
Ezh2 expression was reduced in the endocrine compartment, Ezh1 and Jarid2 RNAs were enriched by two-fold 
(Fig. 5a), indicating that Jarid2 expression is increased in endocrine cells. To test this possibility, we used an ade-
novirus encoding a GFP-tagged version of Ngn3 (Ad.Ngn3:GFP) to transduce mPAC cells and, in agreement with 
our finding in vivo, Jarid2 expression was augmented in transduced (GFP+) cells (Fig. 5b). Altogether, our results 
show that expression of PRC2 components and, specifically, expression of Jarid2, is regulated in the endocrine 
compartment.
To experimentally test a cell-autonomous requirement for Jarid2 in the endocrine lineage, we ablated Jarid2 
in endocrine progenitors (Ngn3-Cre;Jarid2flox/flox, from here on Jarid2Δendo). We obtained embryonic pancreas at 
e15.5, which appeared normal in size and morphology (not shown). As in Jarid2Δpanc, we found a 50% reduction 
in the expression levels of insulin and somatostatin, while glucagon gene expression exhibited a lower decrease 
(Fig. 5c). Of all the early specification genes analyzed, only NeuroD1 appeared downregulated, albeit modestly 
(Fig. 5d), whereas the expression of several genes involved in β-cell differentiation and function such as MafA, 
Pcsk1, Iapp, and G6pc2 were diminished (Fig. 5c).
We also asked whether Jarid2 was required in differentiating β-cells. For this purpose, we generated mice in 
which Jarid2 was ablated from β-cells at the onset of insulin gene expression (Rip-Cre;Jarid2flox/flox, from here on 
Jarid2Δbeta). We performed a morphometric analysis of both insulin and glucagon cell areas, and found that they 
remained unaltered in Jarid2Δbeta newborns (Supplementary Fig. S3). These results show that Jarid2 depletion in 
embryonic β-cells has no significant impact on β-cell numbers at birth.
Figure 4. Jarid2 is required to complete endocrine cell differentiation. (a) Quantification by qRT-PCR of the 
relative expression (mRNA) of the indicated endocrine specification factors (left) and differentiation genes 
(right) in Jarid2WT (n = 11) and Jarid2Δpanc (n = 15) e15.5 pancreases. Bars represent represent mean ± SEM; 
*p < 0.05, **p < 0.001, ***p < 0.0001. (b) Quantification by qRT-PCR of the relative expression of the three 
main pancreatic hormones (left) and the indicated endocrine differentiation genes (right) in Jarid2WT (n = 5) 
and Jarid2Δpanc (n = 6) e17.5 pancreases. Bars represent mean ± SEM; *p < 0.05, **p < 0.001.
www.nature.com/scientificreports/
7SCIEntIfIC RepoRts | 7: 11643  | DOI:10.1038/s41598-017-11691-2
Overall, these findings support that Jarid2 major role in β-cell mass establishment is downstream of Ngn3 and 
before or shortly after the insulin gene is expressed.
Reduced β-cell proliferation during late gestation in Jarid2Δpanc mice. Jarid2 has been shown to 
inhibit cell proliferation during cardiogenesis and neurogenesis14, 25–28, and is required for the scheduled reacti-
vation of epidermal progenitor and stem cells16. Thus, we asked whether de-regulated proliferation in embryonic 
β-cells29, 30 might also contribute to the reduction in β-cell mass in Jarid2Δpanc mice. We quantified cycling insulin 
positive cells at e17.5 by immunostaining using an anti-ki67 antibody and found a ∼30% decrease in Jarid2Δpanc 
relative to controls (Fig. 6a). We also immunostained for Phospho-HistoneH3 (PHH3) and observed a ∼35% 
reduction in the proportion of β-cells that are actively dividing (late G2 and M phases) in Jarid2Δpanc pancreases 
(Fig. 6b).
We next investigated the expression of cell cycle genes in e17.5 whole pancreas. We found that among the 
general cycle regulators analyzed, only Cdkn1a (p21) and Cdk6 appeared modestly downregulated (Fig. 6c). We 
also assessed by manual inspection the behavior of general cell cycle regulators in our microarray data obtained 
at e15.5. Expression of the general cell cycle regulators did not change in the absence of Jarid2, except for Cdkn1a, 
Figure 5. Jarid2 is required downstream of Ngn3 to complete endocrine cell differentiation. (a) Quantification 
by qRT-PCR of the relative expression of the indicated PRC2 components in Ngn3-Cre;dtTomato negative 
and positive cells from e15.5 pancreases. Jarid2 and Ezh1 are significantly enriched in endocrine cells while 
Ezh2 is less abundant. Neurog3 and Pax4 expression are shown as controls. Bars represent mean ± SEM of 3–5 
independent isolations; *p < 0.05, ***p < 0.0001. (b) Quantification by qRT-PCR of the relative expression 
of Jarid2 in Ad:Ngn3-GFP transduced (GFP+) vs non-transduced (GFP-) mPAC cells. Note that Jarid2 is 
modestly upregulated by Neurog3 expression. Expression of Neurog3 (endogenous) and Pax4 genes are shown 
as controls. Bars represent mean ± SEM of 3 independent experiments; ***p < 0.0001. (c) Quantification by 
qRT-PCR of the relative expression of the three main pancreatic hormones (left) and the indicated endocrine 
differentiation genes (right) in Jarid2WT (n = 11) and Jarid2Δendo (n = 12) e15.5 pancreases. Bars represent 
mean ± SEM; *p < 0.05, **p < 0.001, ***p < 0.0001. (d) Quantification by qRT-PCR of the relative expression 
of the indicated endocrine differentiation factors in Jarid2wt (n = 11) and Jarid2Δendo (n = 12) e15.5 pancreases. 
Bars represent mean ± SEM *p < 0.05. Note that except for NeuroD1, key endocrine specification factors 
remained unchanged.
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which appeared downregulated, although not significantly when we validated these results by qRT-PCR using 
a larger set of samples (Fig. 6c). Interestingly, two less known cell cycle regulators, Pak3 and Ripply3, which 
have been recently shown to limit endocrine cell proliferation31, 32, appeared downregulated. We validated these 
Figure 6. Ablation of Jarid2 in pancreatic progenitors results in reduced prenatal β-cell proliferation. (a) 
Percentage of β-cells (ins+) that are Ki67+ in Jarid2WT (n = 3) and Jarid2Δpanc (n = 3) pancreases from e17.5 
embryos. Bars represent mean ± SEM; *p < 0.05. A representative image of the insulin (red) and Ki67 (green) 
immunofluorescence staining is shown on the right. Scale bar: 50 μm. (b) Percentage of β-cells (ins+) that are 
PHH3+ in Jarid2WT (n = 4) and Jarid2Δpanc (n = 3) pancreases from e17.5 embryos. Bars represent mean ± SEM; 
*p < 0.05. A representative image of the insulin (red) and PHH3 (green) immunofluorescence staining is shown 
on the right. Scale bar: 50 μm. (c) Relative expression of the indicated cell cycle regulators in Jarid2WT (n = 6) 
and Jarid2Δpanc (n = 5) e17.5 pancreases. Bars represent mean ± SEM. Note that most of the genes assayed 
remained unchanged. (d) Quantification by qRT-PCR of the relative expression of the cell cycle regulators 
Cdkn1a, Pak3 and Ripply3 at the indicated embryonic stages in Jarid2WT (n = 11 and n = 6 at e15.5 and 17.5, 
respectively) and Jarid2Δpanc (n = 15 and n = 5 at e15.5 and 17.5, respectively) embryonic pancreases. Bars 
represent mean ± SEM. *p < 0.05, ***p < 0.0001.
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observations by qRT-PCR and found that both Pak3 and Ripply3 were decreased by ∼25% at e15.5 (Fig. 6c), but 
these changes did not persist later at e17.5 when β-cells undergo replication (Fig. 6d).
In addition, we determined whether apoptosis could also be affecting the resulting β-cell mass. Tunel assays 
detected no apoptotic β-cells in both control and Jarid2Δpanc pancreases at e17.5 (data not shown). Altogether, 
these results demonstrate that loss of Jarid2 impairs proliferation but not survival of embryonic β-cells. Because 
β-cell formation appears not to be affected in Jarid2Δbeta, it is plausible that the defects in proliferation are deter-
mined at precursor stages.
Jarid2 as a regulator of H3K27me3 and RNAPII-Ser5P during pancreatic endocrine cell differ-
entiation. Jarid2 interacts with PRC2, and G9a/GLP and SETDB1, which bear specificity towards H3K27 and 
H3K9, respectively. To explore the molecular function of Jarid2 in the context of pancreas development, we first 
quantified H3K27me3 and H3K9me2 in total pancreatic lysates from individual e15.5 embryonic pancreas by 
western blot. We found no differences between control and Jarid2Δpanc, although H3K27me3 appeared margin-
ally increased (Supplementary Fig. S4). This lack of broad defects was not due to compensatory changes in PRC2 
components expression in the absence of Jarid2 (Supplementary Fig. S4).
To investigate changes in H3K27me3 specifically in endocrine cell populations (progenitors and descendants) 
vs non-endocrine cell types residing in the pancreas, we isolated YFP+ (endocrine) and YFP− (non-endocrine) 
cells from Ngn3-Cre;Jarid2flox/flox;R26-YFP (Jarid2Δendo) and Ngn3-Cre;Jarid2+/+;R26-YFP (Jarid2WT) pancreases at 
e15.5 and compared the enrichment in H3K27me3 at the promoters of both early endocrine factors and differen-
tiation genes. Interestingly, loss of Jarid2 did not change the enrichment in H3K27me3 in any of the genes tested. 
The enrichment in H3K27me3 at the promoters of the early endocrine factors Insm1, NeuroD1, Pdx1 and Nkx2-2 
in non-endocrine cells (YFP−) was high and diminished in endocrine progenitors and descendants (YFP+) both 
in the presence and absence of Jarid2 (Fig. 7a). Conversely, the enrichment in H3K27me3 at the promoters of the 
endocrine differentiation genes MafA, Pcsk1, G6pc2 and Ins1 was lower in non-endocrine cells (YFP−) as com-
pared to that of the early endocrine factors and did not decrease further in endocrine progenitors and descend-
ants (YFP+) (Fig. 7a). Again, Jarid2 ablation had no impact in this pattern. Altogether, these experiments suggest 
that the defects in the initial expression of endocrine differentiation genes observed in Jarid2Δpanc and Jarid2Δendo 
are likely independent of a potential role of Jarid2 in the regulation of H3K27me3.
Figure 7. Jarid2 modulates the deposition of RNAPII-Ser5p at the promoters of endocrine genes. (a) 
Chromatin immunoprecipitation assays to determine H3K27me3 abundance at the promoter regions of early 
endocrine transcription factors and endocrine differentiation genes in the indicated cell populations isolated 
from Ngn3-Cre;Jarid2flox/flox;R26-YFP (Jarid2Δendo) and Ngn3-Cre;Jarid2+/+;R26-YFP (Jarid2WT) pancreases at 
e15.5. Data is presented as % enrichment of input. MyoD and Actb are shown as positive or highly enriched 
and negative controls, respectively. Bars represent mean ± SEM of 4 independent experiments. (b) Chromatin 
immunoprecipitation assays to determine RNAPII-Ser5p abundance at the promoter of the indicated genes 
in control e15.5 pancreases. Numbers are calculated as % enrichment of input and expressed relative to Actb, 
which is given arbitrarily the value of 1. Bars represent mean ± SEM for 6 independent experiments. Note that 
RNAPII-Ser5p abundance varies among genes, being the highest in endocrine gene markers. (c) Chromatin 
immunoprecipitation assays to determine RNAPII-Ser5p abundance at the promoter of the indicated genes 
in Jarid2WT and Jarid2Δpanc e15.5 pancreases. Data is presented as fold change in % enrichment of input for 6 
independent experiments. Bars represent mean ± SEM; *p < 0.05.
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Jarid2 is involved in the correct deposition of RNAP phosphorylated at Ser5 (RNAPII-Ser5P) at PRC2 tar-
get gene promoters in stem cells33. This post-translational modification is important for transcriptional prim-
ing of genes34. Therefore, we hypothesized that, similar to stem cells, Jarid2 might be regulating deposition of 
RNAPII-Ser5P at endocrine gene promoters. Thus, we analyzed RNAPII-Ser5P enrichment by chromatin 
immunoprecipitation in Jarid2WT and Jarid2Δpanc e15.5 pancreases. Given the fact that efficient ChIP using a 
phospho-specific antibody requires a high amount of starting material, we used whole pancreatic cell lysates. 
Analysis of the enrichment of RNAPII-Ser5P revealed that RNAPII-Ser5P levels varied greatly among the pro-
moters of the genes studied, being particularly high at promoters of the endocrine genes NeuroD1, G6pc2, Pcsk1, 
Ins1 and Sst (Fig. 7b). Remarkably, RNAPII-Ser5P levels were significantly reduced by ∼40% in Jarid2Δpanc pan-
creases compared to controls (Fig. 7c). Altogether, our results suggest that Jarid2 plays a role in priming endo-
crine genes for their appropriate expression during endocrine differentiation.
Discussion
Results presented in this study demonstrate that Jarid2 is required during mouse pancreatic endocrine cell for-
mation to establish the proper β-cell population at birth. Thus, ablation of Jarid2 in pancreatic and endocrine 
progenitors disrupts activation of the β-cell gene expression program as well as prenatal β-cell expansion leading 
to reduced β-cell mass in newborn mice.
In the absence of Jarid2, fewer insulin-expressing β-cells form during the secondary transition. Our 
genome-wide expression analysis reveals that loss of Jarid2 does not broadly affect pancreatic endocrine gene 
expression. Instead, only a small subset of endocrine genes is significantly reduced upon Jarid2 loss. Several of 
these genes code for functional and mature β-cell markers, while genes involved in early endocrine specification 
remain unaffected. Interestingly, Jarid2 expression is enriched, in endocrine progenitors and descendants in vivo 
and induced upon overexpression of Ngn3 in mPAC cells, indicating that Jarid2 itself may constitute part of the 
endocrine differentiation program.
Our experiments comparing isolated endocrine and non-endocrine cells rule out a major role of Jarid2 in the 
regulation of H3K27me3 levels downstream of Ngn3. Of all the 217 genes downregulated in the absence of Jarid2, 
it is possible that neither endocrine transcription factors nor differentiation genes are direct targets, which might 
explain why we did not detect changes in the enrichment in H3K27me3 at their promoters. However, it is also 
possible that chromatin immunoprecipitation assays are not powerful enough to detect subtle changes, as those 
caused by Jarid2 ablation. Indeed, the effects of Jarid2 loss in gene expression in the pancreas are not dramatic and 
Jarid2 effects on H3K27me3 in other contexts have been shown to be modest10, 11, 35. Nonetheless, our observation 
that expression of early endocrine specification transcription factors is associated with loss of H3K27me3 at their 
promoters, while initial embryonic expression of endocrine differentiation genes is not accompanied by loss of 
this mark, which is already low at these promoters (Fig. 7), raises the possibility that Jarid2 plays a bigger role in 
the activation of genes exhibiting low H3K27me3 enrichment.
H3K27me3 is often found together with the initiating form of RNAPII, RNAPII-Ser5P, which has been 
proposed to prime genes for fast and efficient activation in response to differentiation33, 34. Our analysis of 
RNAPII-Ser5P at the promoters of β-cell differentiation genes indicates that loss of Jarid2 results in diminished 
RNAPII-Ser5P, an alteration that may possibly account for their defective expression, as previously reported in 
mESCs33. Interestingly, our findings are in sharp contrast with the consequences of loss of Ezh2 in pancreatic pro-
genitors. Loss of Ezh2 enhances endocrine cell induction8 whereas loss of Jarid2 is detrimental for the complete 
induction of the β-cell differentiation program, resulting in opposite phenotypes. The antagonistic outcomes of 
the ablation of Ezh2 and Jarid2 in the same cell populations further argue that Jarid2 would function as a tran-
scriptional activator rather than a repressor.
Among the genes whose expression is reduced in Jarid2Δpanc at e15.5 we found the cell cycle regulator Pak3. 
Interestingly, global loss of Pak3 results in increased Ngn3-positive cell numbers and a transient impairment in 
β-cell differentiation32. In the context of our study, these observations raise the possibility that Jarid2Δpanc primary 
defect is de-regulated cell cycle exit at e15.5, which subsequently impacts differentiation. However, endocrine cell 
numbers in Pak3−/− mice recover prenatally32 and mRNA levels of main components of the cell cycle machinery 
are not de-regulated in Jarid2Δpanc pancreases, suggesting that Jarid2 has broader effects and its primary function 
is not cell cycle gene regulation. Interestingly, during heart development, Jarid2 effects on the cell cycle are likely 
context-dependent differing temporarily and among the distinct cell layers of the heart36. In the skin, Jarid2 
is required for the scheduled activation of adult stem cells in the hair follicle, through the inhibition Cdkn2a 
expression16. In our study, differentiated embryonic β-cells fail to re-entry the cell cycle at the end of gestation but 
we did not detect up-regulation of Cdkn2a (p16/ink4a) expression. Previous studies in mouse have shown that 
Jarid2 is required during heart formation and in neural cells within the brain to repress CyclinD1 and promote 
differentiation14, 25–28, 37. Contrarily, in the pancreas, loss of Jarid2 results in the opposite effect. In this scenario 
and considering the preceding defects in endocrine cell differentiation, it is also possible that the consequences of 
Jarid2 loss in β-cell proliferation are secondary to their impaired differentiation. Supporting this notion, specific 
deletion of Jarid2 in β-cells after the onset of insulin expression does not affect neonatal beta cell mass as assessed 
by morphometric analysis.
A previous study reported that in vitro generated β-cells display aberrant H3K27me3 and H3K4me3 modifica-
tion patterns, indicating that the directed differentiation protocol failed to completely recapitulate the epigenetic 
changes that occur in vivo38. In fact, it has been suggested that the generated α- and β-cells are missing important 
epigenetic modifications, and that histone modifying enzymes may be involved in fine-tuning development and 
function of pancreatic cell types4–6. Thus, in this context, our findings that Jarid2 regulates transcriptional priming 
of β-cell differentiation genes in vivo may have important implications in the development of stem cell-based and 
cell replacement therapies and therefore, the role of Jarid2 in the in vitro generation of β-cells warrants further 
investigation.
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Methods
Mice. Mice were bred and maintained at the barrier animal facility of the University of Barcelona. Embryonic 
tissues were collected at indicated times, considering the morning of the appearance of a vaginal plug as embry-
onic day (E) 0.5. Principles of laboratory animal care were followed (European and local government guide-
lines) and animal procedures were approved by the Animal Research Committee of the University of Barcelona. 
Animals were euthanized by cervical dislocation. Pdx1-Cre39, 40, Neurog3-Cre41, Rip-Cre42, Jarid2flox/flox 43, mem-
brane-targeted tdTomato44 and R26R-EYFP45 mice have been described previously. Mice were genotyped with 
primers provided in Table S2. Animals with deletion of Jarid2 in early pancreatic progenitors, in endocrine pro-
genitors and in β-cells crossing mice carrying a conditional allele of Jarid2 (Jarid2flox) with transgenic Pdx1-Cre, 
Neurog3-Cre and Rip-Cre, respectively.
Insulin content. Pancreases from newborn mice were dissected and proteins were recovered using a stand-
ard acid extraction and insulin content was quantified by ELISA assays (Mercodia, Uppsala, Sweden).
Intraperitoneal Glucose Intolerance Test (ipGTT). The ipGTT was performed after 5–6 h of food dep-
rivation by administration of an injection of D-glucose (2 g/Kg body weight), and glycaemia from tail vein blood 
samples was measured at 0, 15, 30, 60 and 120 minutes after injection using a clinical glucometer and Accu-Check 
test strips (Roche Diagnostics, Switzerland).
Immunofluorescence and morphometric analysis. Embryonic and P0 pancreases were fixed in 4% 
paraformaldehyde (PFA) (Electron Microscopy Sciences, Hatfield, PA) for 3–6 h. Adult pancreases were fixed in 
4% formalin overnight. Tissues were subsequently washed, dehydrated, embedded in paraffin wax, and sectioned 
at 3 μm. For immunofluorescence, a standard immunodetection protocol was followed as described in ref. 46. 
Briefly, tissues were rehydrated and, when required, subject to heat-mediated antigen retrieval in citrate buffer. 
After a blocking step in 5% donkey serum/0.2% Triton X-100, tissue sections were incubated overnight with 
primary antibodies and then for 1 h with secondary antibodies (Table S3). Nuclei were stained with Hoechst 
33258 (Sigma). Fluorescent images were captured using a Leica DMI 6000B widefield microscope or a Leica TCS 
SPE confocal microscope. For morphometrical analysis, e15.5 pancreas was sectioned at 3 μm and distributed as 
serial sections onto sets o or 5 slides. At least 10 sections 45 μm apart per animal for area, insulin and glucagon 
morphometries were analyzed. For adult pancreas morphometry, 6 sections per animal (2 × tail, 2 × body and 
2 × head) were analyzed. For Ngn3+ morphometry, 4–6 sections per animal were analyzed. For ChgA morpho-
metry, >2000 ChgA+ cells per animal were counted. For Ki67 and PHH3 morphometries, 2500–3000 insu-
lin+ nuclei were counted. Morphometric analyses were performed using ImageJ software (http://rsb.info.nih.
gov/ij/index.html).
RNA isolation. Total RNA was isolated from tissues using the RNeasy kit (Qiagen, Hilden, Germany) and 
from sorted cells using the NucleoSpin XS RNA kit (Mackerey-Nagel, Düren, Germany). First-strand cDNA was 
prepared using the Superscript III RT kit and random hexamer primers (Invitrogen, Carlsbad, CA, USA). Reverse 
transcription reaction was carried for 90 min at 50 °C and an additional 10 min at 55 °C.
Real-time PCR. Real time PCR (qRT-PCR) was performed on an ABI Prism 7900 sequence detection sys-
tem using SybrGreen reagents: Express Greener (Invitrogen, Carlsbad, CA, USA) or GoTaq® qPCR Master Mix 
(Promega Biotech Ibérica, Alcobendas, Madrid, Spain). Expression relative to a housekeeping gene was calculated 
using the deltaCt method. We picked the moderately expressed gene Tbp as housekeeping for all the genes except 
for the pancreatic hormones and Iapp, which are more abundant, and whose expression was compared to that of 
Actb. Primer sequences are provided in Table S2.
Global gene expression profiling. RNA from embryonic pancreases was hybridized onto GeneChip® 
Mouse Genome 430 2.0 Array (Affymetrix). Total RNA was isolated using the RNeasy kit (Qiagen, Hilden, 
Germany). Expression data were normalized with RMA, and the LIMMA package was used for statistical analysis 
to identify differentially expressed genes. Data have been deposited in Gene Expression Omnibus (www.ncbi.nlm.
nih.gov/geo), accession number GSE77238. The DAVID Functional Annotation Tool (http://david.abcc.ncifcrf.
gov) was used to identify enriched functional categories in differentially expressed genes (log2Fc < −0.29).
Calculation of tissue-specificity scores. Publicly available gene expression profiles of pancreatic islets, 
β-cells, exocrine pancreas, liver, cerebral cortex, hypothalamus, skeletal muscle, kidney, lung and spleen7, 22, 47 
were downloaded and normalized together with the embryonic pancreas samples. From these data, we generated 
a tissue-specificity score for each gene in each tissue, defined as the log2-ratio between the expression of a par-
ticular gene in the reference tissue and the median of its expression in all tissues, and considered a value > 4 to 
indicate tissue-specificity.
Pancreatic cell dispersion and flow cytometry. Pancreatic buds were harvested from e15.5 embryos 
and treated with 0.125% trypsin-EDTA (Life Technologies) and 50ng/ml Dnase I (Stem cell) with agitation for 
10–15 min at 37 °C. Digestion was inactivated by addition of 0.4volumes of FBS (falta provider). Transduced 
mPAC cells were collected after trypsinization in 15 ml tubes, pelleted and ressuspended to ∼2 × 106 cells/ml in 
RPMI+3% FBS. Sorting was performed using a BD FACSAria SORP (for tomato) or BD FACSariaII (for GFP 
and YFP) machine, and cells were recovered in RNA lysis buffer or FBS for RNA extraction and ChIP assays, 
respectively.
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Cell culture and viral treatment. mPAC cells were grown in DMEM-4.5 g/L glucose (Sigma-Aldrich, St 
Louis, MO, USA) plus antibiotics supplemented with 10% FBS. For adenoviral transduction experiments, mPAC 
cells were seeded onto 10 cm plates and treated one day later with Ad.Ngn3-GFP adenoviruses (purified) at a 
multiplicity of infection (moi) of 10 unless otherwise indicated O/N. Cells were harvested for FACS sorting ∼42 h 
after transduction. The bicistronic adenovirus encoding Ngn3-GFP was kindly provided by Dr. H. Heimberg48.
Chromatin immunoprecipitation. E15.5 embryonic pancreases were fixed in 1% formaldehyde for 10 min 
at room temperature with rotation. Fixation was quenched with 0.125 M glycine for 5 min, and pancreases were 
washed three times for 5–10 min in PBS and stored at −80 °C until further processing. Histone ChIPs were per-
formed as described elsewhere49. ChIPs against RNAPII-Ser5P were performed following the protocol described 
by Stock JK, Bookes E and Pombo A in http://www.epigenesys.edu/en/protocols (prot48) with some modifica-
tions: 3–6 e15.5 fixed pancreases were resuspended in 150–200 μl SDS Lysis Buffer supplemented with phos-
phatase and protease inhibitors and sonicated in a Bioruptor (Diagenode) for 6 cycles of 5 min each (30 sec ON 
30 sec OFF) at High setting. After removing cellular debris by centrifugation chromatin was diluted 10-fold in 
ChIP dilution buffer and 30–70 μg were immunoprecipitated with 3 μg of Anti-RNA polymerase II CTD repeat 
YSPTSPS antibody [H14] - ChIP Grade (Abcam) and 20 μl of bridged ProteinG Dynabeads (Life Technologies) as 
described by Stock JK, Bookes E and Pombo A in http://www.epigenesys.eu/en/protocols (prot48). Washes were 
performed as described by Stock JK et al. and elutions as described in ref. 49. For histone ChIPs from sorted pan-
creatic cells, we adapted the protocol for low-cell number ChIP detailed in ref. 9. Briefly, 30,000–60,000 cells were 
collected in 50 ul FBS, and fixed in 500 ul with 1% formaldehyde for 10 min at room temperature with rotation. 
Fixation was quenched with 0.125 M glycine for 5 min and cells were washed as described by Xu et al.9. Cells were 
resuspended in 100 ul of SDS-lysis buffer and stored at −80 °C until further processing. After storage, Jarid2wt and 
Jarid2Δendo cells were processed in parallel. Chromatin was diluted 10-fold in ChIP dilution buffer before immu-
noprecipitation with 1 μg of the antibodies listed in Table S3. Immunoprecipitated chromatin (specific antibody 
and IgG control) was analyzed, together with inputs, by real-time PCR as described above. Percentage of input 
was calculated as follows:
− .−   −   ‐ ‐2 2(Ct antibody Ct input) (Ct IgG Ct input)
Immunoblotting. Embryonic pancreases were lysed in triple detergent lysis buffer (Tris-HCl 50 mM, NaCl 
150 mM, 0.1% SDS, 1% NP40 and 0.5% Sodium Deoxycholate) and extraction of histones was optimized through 
the addition of HCl to a final concentration of 0.2 N. After 30 min incubation on ice, cell debris was pelleted and 
supernatants were quantified and prepared for SDS-PAGE electrophoresis on 16% Tris-tricine homemade gels. 
Proteins were then transferred to a Polyscreen PVDF membrane (Perkin Elmer, Waltham, MA, USA) and incu-
bated overnight at 4 °C with the antibodies indicated Table S3. Blots were visualized with ECL Reagent (Pierce 
Biotechnology, Rockford, IL, USA) using a LAS4000 Lumi-Imager (Fuji Photo Film, Valhalla, NY). Protein spots 
were quantitated with Image J software (http://rsb.info.nih.gov/ij/index.html).
Statistics. Data are presented as mean ± standard error of the mean (SEM). Statistical significance was tested 
using unpaired Student’s t-test, or 2-way ANOVA for the ipGTT.
Study approval. Animal procedures were approved by the Animal Research Committee of the University 
of Barcelona.
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